All News

The FDA announced draft guidance to remove clinical efficacy studies for biosimilars and also issued the position that all biosimilars in the US should be interchangeable.

Increasing respiratory syncytial virus (RSV) vaccination among older adults could prevent up to 1600 deaths and 20,000 hospitalizations over 5 years.

Premiums for coverage on the ACA marketplaces are set to jump by an average of 26% next year, even before the expiration of subsidies is factored in.

The antiretroviral (ART) regimen Biktarvy showed higher 1-year ART persistence and lower switch rates among people with HIV.

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

Real-world data suggest metabolic dysfunction-associated steatotic liver disease is also associated with higher all-cause mortality.

Previous research has evaluated PD-1/PD-L1 immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), but research in the setting of limited-stage disease is sparse.

Symptoms of dry eye improved when patients in Canada used reproxalap compared with a placebo dose.

Radiomic assessment has been used to distinguish multiple sclerosis from similar disorders, and it might also be useful in identifying MS stages and subtypes.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.

Overlapping metabolic mechanisms drive both chronic kidney disease (CKD) and valvular heart disease (VHD), a new review outlined.

Cardiac adverse events were lower among patients taking zanubrutinib compared with ibrutinib in the real-world setting.

In the midst of a government shutdown, former House Speaker Paul Ryan urges clear policies, AI innovation, and patient-focused solutions to build a sustainable US health care system.

Structural and microbial findings point to a potential nasal-brain immune connection in patients with multiple sclerosis (MS).

A multidisciplinary approach that includes addressing social determinants of health reduces time to remission despite higher initial costs.

Researchers found more local pharmacies than facilities that prescribed pre-exposure prophylaxis (PrEP) in areas of high case load.

Posters presented at AMCP Nexus 2025 found especially low oral HIV PrEP uptake among transgender individuals and those facing insurance challenges.

Payers cited high upfront costs, long-term uncertainty, and narrow coverage criteria as factors continuing to limit access and reimbursement innovation.

Attorney General Ken Paxton claims the manufacturers marketed acetaminophen toward pregnant women despite the “known dangers” to unborn children.

AI can transform health care by processing vast data, enhancing decision-making, and addressing biases, but needs remain for transparency and human oversight.

Explore the future of cancer treatment with tumor-agnostic therapies, as experts unveil promising trials and innovative drug developments at ESMO.

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Synovial sarcoma—a rare, aggressive soft tissue cancer—can present as a painless hand swelling that mimics a harmless lesion, underscoring the need for early recognition and improved diagnostic access in low-resource settings.

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.

Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, advocate for improved proactive management of myasthenia gravis (MG) for better patient outcomes.

New research highlights rising opioid use disorder (OUD) diagnoses among youth, emphasizing the need for improved screenings and mental health support.

National data show adults struggling to afford energy bills face over twice the odds of depression and anxiety.

The FDA has expanded sotatercept's indications for pulmonary arterial hypertension, following data showing significant drops in hospitalization and mortality risks.

More than 50% of patients with psoriasis are eligible for systemic treatment, and nearly 90% would switch to an effective oral therapy with a favorable safety profile.

Multidrug combinations may counteract the role of cytokines in drug resistance, a new review article explains.